Fang Yi
Professor, Chief Pharmacist, Master's Supervisor
Research Interests: Clinical Pharmacology; Clinical Pharmacokinetics; Quantitative Pharmacology; Pharmacogenomics; Early Clinical Evaluation of Innovative Drugs; PK/PD Studies of Biotechnology Drugs; Evaluation and Translation of Immunotherapies for Autoimmune Diseases and Cancer
Tel: +86-010-86491332
Email: fygk7000@163.com
EDUCATION
Doctor of Medicine, Ocean University of China (2003-2007)
Bachelor of Science, West China University of Medical Sciences (1990-1995)
PROFESSIONAL EXPERIENCE
2025 - present Guangzhou University of Chinese Medicine, The Seventh Clinical Medical College
Doctoral Supervisor
2024 - present Guangxi Medical University, State Key Laboratory of Targeted Oncology
Doctoral Supervisor
2018 - present Guangzhou Medical University, School of Pharmacy
Part-time Professor / Master's Supervisor
2013 - present Peking University, School of Pharmaceutical Sciences
Master's Supervisor, Department of Pharmacy Administration and Clinical Pharmacy
2008 - present Peking University People's Hospital, Phase I Clinical Trial Research Unit
Deputy Chief Pharmacist / Professor (2008)
Chief Pharmacist / Professor (2015)
1995–2008 Chinese PLA General Hospital, Clinical Pharmacology and Pharmacy Research Laboratory
Research Trainee (1995)
Pharmacist-in-Charge (2001)
Deputy Chief Pharmacist (2006)
ACADEMIC APPOINTMENTS
Deputy Director, Innovation Translation and Clinical Development Committee, China Pharmaceutical Innovation and Research Association (2025)
Member, Phase I Clinical Research Committee, DIA China (Drug Information Association) (2025)
Deputy Director, Clinical Pharmacology Committee, Chinese Pharmacological Society (2020)
Deputy Director, Quantitative Pharmacology Committee, Chinese Pharmacological Society (2019)
Standing Committee Member, Drug Clinical Trial Committee, Chinese Pharmacological Society (2018)
Standing Committee Member, Epigenetic Pharmacology Committee, Chinese Pharmacological Society
Standing Committee Member, Pharmacogenomics Committee, Chinese Pharmacological Society
Standing Committee Member, Marine Drug Pharmacology Committee, Chinese Pharmacological Society
Long-term External Expert, Center for Drug Evaluation, National Medical Products Administration
Executive Vice Chairman of the Council, Zhongguancun Jiutai Clinical Trial Technology Innovation Alliance
Executive Vice Chairman, South China Biomedical Innovation R&D Technology Service Alliance
Expert Database Member, Center for Drug Evaluation, National Medical Products Administration (NMPA)
GCP Certification & Inspection Expert Database Member, Center for Drug Inspection, NMPA
Science and Technology Expert, Investment Evaluation Center, Ministry of Finance
Editorial Board Member, Chinese Journal of Clinical Pharmacology
Editorial Board Member, Chinese Journal of Clinical Pharmacology and Therapeutics
Core Expert, Guizhou Provincial Government's "Medical & Health Aid to Guizhou Initiative"
Honorary Director, Clinical Research Center / Honorary Director, Phase I Clinical Research Center, The Fifth Affiliated Hospital of Guangzhou Medical University
AWARDS AND CERTIFICATES
1. One authorized invention patent: "A Novel Alginate Monoclonal Antibody and Its Preparation Method"
2. Leading Talent, "Canal Talent" Program, Beijing Sub-Center / Tongzhou District, Beijing (2024)
3. 2nd Prize, China Medical Science and Technology Award - "Development of a Novel Psoriasis Drug: Aryl Hydrocarbon Receptor Modulator" (2023)
4. 1st Prize, Guangdong Pharmaceutical Association Hospital Pharmacy Science and Technology Award - "Resource Integration and Achievement Translation for the Early Clinical Trial Evaluation Technology Platform of Biotechnology Drugs for Malignancy and Autoimmune Disease Treatment" (2023)
5. Outstanding Party Member of Peking University People's Hospital (2020)
6. Advanced Worker of Peking University People's Hospital (2019)
7. 2nd Prize, Chinese Pharmaceutical Association Science and Technology Award - "Series of Studies on Novel Mechanisms of Antimicrobial Resistance and Corresponding Strategies" (2006)
8. 2nd Prize, Beijing Science and Technology Award - "Series of Studies on the Diagnosis & Treatment of Respiratory Infections and the Rational Use of Antimicrobials" (2005)
9. People's Liberation Army Science and Technology Progress Award
(1) 3rd Prize - "Standardization and Application Value of Clinical Pharmacological Research for New Drugs in Military Hospitals" (2003)
(2) 2nd Prize - "Series of Studies on Post-Antibiotic Effect and Optimization of Dosing Regimens" (2001)
REPRESENTATIVE PUBLICATIONS
1. Rui Ding, Fan Huang, Ziyan Ding, Yanting Li, Qun Gu, Fang Men, Chongyou Lee, Jiaojiao Zhang, Wenyan Zhao, Qian Wang, Yian Liu, Shuang Li, Qingshan Zheng, Haifeng Song, Liming Chen,
Wei Wang, Suping Niu, Yi Fang*. Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a novel anti-TSLP bispecific antibody (GR2002) in healthy Chinese adults:
A randomized, placebo-controlled phase 1 trial. Eur J Pharm Sci. 2026 Jan 8;218:107432. (IF=4.7)
2. Haimei Xu, Chen Li, Rui Ding, Yaoxuan Zhan, Haiyan Liu, Xintong Liang, Yuanchen Niu, Ying Luo, Zhiqin Hu, Jin He, Liming Chen, Tenghua Wang, Yi Fang*. Efficacy and safety of
non-conventional synthetic disease-modifying antirheumatic drugs in early active rheumatoid arthritis: a network meta-analysis. BMC Rheumatol. 2025 Dec 5;10(1):5. (IF=2.5)
3. Yuanchen Niu, Yufang Wang, Changhong Huo, Yi Fang*. Global research trends in renal anemia: a multidimensional bibliometric study. Ren Fail. 2025 Dec;47(1):2580457. (IF=3.0)
4. Zhiqin Hu, Tenghua Wang, Xiaoqiang Li, Ying Luo, Xiaole Wang, Chen Li, Zhixin Zhang, Xuan Wang, Jin He, Yaoxuan Zhan, Xintong Liang, Sichao Zheng, Yongmei Li, Yindong Zong,
Lizhong Liu, Jinlian Bi, Yongdong Zhang, Na Zhou, Haiyan Liu, Li Ban, Dajiang Qin, Yi Fang*. A Multicenter, Randomized, Open-Label, Active-Controlled, Parallel-Group Study
Evaluating the Pharmacokinetics of Single-Dose Tapentadol Hydrochloride Intravenous Infusion and Tapentadol Hydrochloride Oral Tablets in Patients with Pain.
Eur J Drug Metab Pharmacokinet. 2025 Nov;50(6):529-539. (IF=2.4)
5. Ziyan Ding, Hui Zhang, Fan Huang, Yian Liu, Qian Zhou, Dingyuan Hu, Liming Chen, Yanting Li, Rui Ding, Xiaoyan Nie, Yi Fang*. Efficacy and Safety of Biologics for Systemic Lupus
Erythematosus (SLE): A Systematic Review and Network Meta-Analysis. Clin Rev Allergy Immunol. 2025 Jul 23;68(1):70. (IF=11.3)
6. Dingyuan Hu, Suping Niu, Fan Huang, Lu Jin, Qun Gu, Yanting Li, Chongyou Lee, Zhenwei Xie, Xiangxing Liu, Fang Men, Wenyan Zhao, Shuang Li, Yian Liu, Qian Wang, Huaying Fan,
Jiaojiao Zhang, Shuangshuang Lin, Liming Chen, Yi Fang*. Pharmacokinetics, pharmacodynamics, and safety interaction study of tunodafil hydrochloride and alcohol: A randomized, blinded,
placebo-controlled, three-cycle crossover study in Chinese healthy men. Andrology. 2025 Jul 7. (IF=3.4)
7. Fan Huang, Dingyuan Hu, Huaying Fan, Binyi Hu, Yian Liu, Wenliang Dong, Xiangxing Liu, Yanting Li, Diqin Yan, Rui Ding, Suping Niu, Liming Chen, Xiaoyan Nie, Yi Fang*. Efficacy
and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta-Analysis. Clin Pharmacol Ther. 2025 Mar;117(3):659-669. (IF=5.5)
8. Liang Xin, Haoxiang Zhu, Suping Niu, Xie Han, Hongxian Pang, Jiangfan Li, Ye Hu, Xuhong Wang, Lujin Li, Yi Fang*. Pharmacodynamic characteristics and influencing factors of tapentadol
for chronic pain relief under dose titration. Front Pain Res (Lausanne). 2025 Jan 17;5:1474529. (IF=2.7)
9. Yanting Li, Zhenwei Xie, Liming Chen, Xiangxing Liu, Shuang Li, Shichun Ye, Hongyan Tang, Chongyou Lee, Qun Gu, Fang Men, Jiaojiao Zhang, Dingyuan Hu, Yuanli Jiang, Xiaochun Wang,
Qian Wang, Yufei Feng, Suping Niu, Yan Liu, Yi Fang*. An exploratory study of drug concentration and inhibitory effect of cetylpyridinium chloride buccal tablets on SARS-CoV-2 infection
among 10 Chinese subjects. Fundam Clin Pharmacol. 2024 Jun;38(3):579-587. (IF=2.5)
10. Ying Luo, Chen Li, Yuanchen Niu, Shuanzhi Wu, Jingyuan Tian, Zhiqin Hu, Jin He, Zhixin Zhang, Haiyan Liu, Yongmei Li, Tenghua Wang, Yi Fang*. Pomalidomide combined with
dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis. Expert Rev Hematol. 2024 Apr-May;17(4-5):127-134. (IF=2.1)
11. Wenliang Dong, Xiaowen Hu, Caiying Wu, Gengchen Wang, Yi Fang*, Luwen Shi, Xiaoyan Nie. Efficacy, safety, and cost-effectiveness of therapeutic drug monitoring (TDM) for TNF
inhibitor therapy in rheumatic disease: A systematic review and meta-analysis. Semin Arthritis Rheum. 2023 Dec;63:152302. (IF=4.4)
12. Shuanzhi Wu, Tenghua Wang, Jieyun Li, Zhixin Zhang, Chen Li, Shuangshuang Xiao, Jin He, Xuan Wang, Zhiqin Hu, Xiaole Wang, Sichao Zheng, Xintong Liang, Guiying Chen, Yongmei Li,
Xianbo Li, Yaoxuan Zhan, Qinwen Zou, Hongliang Jiang, Qingshan Zheng, Li Ban, Haiyan Liu, Yi Fang*. First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual
inhibition of factor Xa and factor IIa. Expert Opin Investig Drugs. 2023 Jul-Dec;32(11):1085-1094. (IF=4.1)
13. Xiangxing Liu, Binyi Hu, Nan Peng, Liming Chen, Dingyuan Hu, Jiaojiao Zhang, Lijue Wang, Zhenwei Xie, Suping Niu, Qian Lu, Jin Lu, Yi Fang*. Evaluation of Bruton tyrosine kinase
inhibitors monotherapy and combination therapy in lymphocytic leukemia. Clin Exp Med. 2023 Dec;23(8):4237-4248. (IF=3.5)
14. Xuan Wang, Xintong Liang, Tenghua Wang, Yaoxuan Zhan, Haiyan Liu, Chen Li, Xianbo Li, Hui Ma, Zhiqin Hu, Xiaole Wang, Shuangshuang Xiao, Li Ban, Jin He, Yongmei Li, Yi Fang*.
Biosimilarity Assessment of the Biosimilar Teriparatide Candidate and the Reference Drug in Healthy Subjects. Clin Pharmacol Drug Dev. 2023 May;12(5):518-524. (IF=1.8)
15. Dingyuan Hu, Liming Chen, Diqin Yan, Wenliang Dong, Min Chen, Suping Niu, Simin Wang, Jiaojiao Zhang, Xiaoyan Nie, Yi Fang*. Effectiveness and safety of anti-BCMA chimeric
antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials. Front Pharmacol. 2023 Jun 20;14:1149138. (IF=4.8)
16. Chen Li, Haiyan Liu, Yixiang Liao, Yu Zhu, Jingyuan Tian, Xuan Wang, Zhiqin Hu, Yaoxuan Zhan, Xianbo Li, Xintong Liang, Jin He, Yongmei Li, Dewei Shang , Qingshan Zheng,
Tenghua Wang, Haifeng Song, Yi Fang*. Phase Ⅰ Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy
Chinese Adults. Biodrugs. 2023; 37:721–735. (IF=7.744）
17. Diqin Yan, Suping Niu, DingyuanHu, Wenliang Dong, YunjuanSun, Qian Wang, SiminWang, Qun Gu, Gang Liu, JiaxueWang, Liming Chen, Jie Lv, QingshanZheng, Haifeng Song, and Yi Fang*.
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults:
A randomized controlled dose-escalation study. Expert Opinion On Investigational Drugs. 2023;2.20. 10.1080/13543784.2023.2178894. (IF=6.498）
18. Xuan Wang, Xintong Liang, Tenghua Wang, Yaoxuan Zhan, Haiyan Liu, Chen Li, Xianbo Li, Hui Ma, Zhiqin Hu, Xiaole Wang, Shuangshuang Xiao, Li Ban, Jin He, Yongmei Li, Yi Fang*.
Biosimilarity Assessment of the Biosimilar Teriparatide Candidate and the Reference Drug in Healthy Subjects. Clinical Pharmacology in Drug Development. 2023，12（5）:518-524. （IF=2.151）
19. Xiangxing Liu, Jiaojiao Zhang, Keqing Feng , Simin Wang , Liming Chen, Suping Niu , Qian Lu and Yi Fang*. Efficacy and safety of oncolytic virus combined with chemotherapy or
immune checkpoint inhibitors in solid tumor patients: A meta-analysis. Frontiers in Pharmacology. 2022;11.14. 10.3389/fphar.2022.1023533.（IF=5.988)
20. Diqin Yan, Huaying Fan, Min Chen, Lin Xia, Simin Wang, Wenliang Dong, Qian Wang, Suping Niu, Huiying Rao, Liming Chen, Xiaoyan Nie, and Yi Fang*. The efficacy and safety of
JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies. Frontiers in Pharmacology. 2022;13. 10.3389/fphar.2022.950450.（IF=5.988)
21. Suping Niu, Min Chen, Diqin Yan, Xiangxing Liu, Shuren Guo, Lun Ou, Huaying Fan, Jie Lv, Qian Wang, Wenliang Dong, Lin Xia, Simin Wang, Gang Liu, Qun Gu, Danjie Guo,
Hongxia Liu, Huiying Rao, Qingshan Zheng, Xiaoyan Nie, Haifeng Song and Yi Fang*. A randomized controlled dose-escalation study of LY06006, a recombinant humanized monoclonal
antibody to RANKL, in Chinese healthy adults. Frontiers in Pharmacology. 2022;13. 10.3389/fphar.2022.893166.（IF=5.988)
22. Linxiao Zhang, Liangying Gan, Kexin Li, Panpan Xie, Yan Tan, Gang Wei，Xiaojuan Yuan，Raymond Pratt，Yongchun Zhou, Ai-Min Hui，Yi Fang*, Li Zuo, Qingshan Zheng.
Ethnicity Evaluation of Ferric Pyrophosphate Citrate among Asian and Non-Asian populations: A Population Pharmacokinetics Analysis. European Journal of Clinical Pharmacology.
2022; 10.1007/s00228-022-03328-9.（IF=3.064,JCR Q3区)
23. Liangying Gan, Panpan Xie, Yan Tan, Gang Wei, Xiaojuan Yuan, Zhifei Lu, Raymond Pratt, YongChun Zhou, Ai-Min Hui, Kexin Li, Yi Fang*, Li Zuo. Pharmacokinetics and Safety
of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease. Drugs in R&D. (IF=3.023)
24. Wenliang Dong, Min Chen, Suping Niu, Bianzhen Wang, Lin Xia, Jiaxue Wang, Tiantian Shen, Qian Wang, Jie Lv, Gang Liu, Huayiing Fan, Zhenwei Xie, Fan Xie, Youzhong An,
Qingshan Zhen, Huiying Rao, Haifeng Song, Yi Fang*. Pharmacokinetic bioequivalence, safety,and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in
Chinese healthy males: a randomized clinical trial. Expert Opinion on Biological Therapy. 2022;22(2):253-262. (IF=5.589）
25. Lin Xia，Tiantian Shen， Wenliang Dong， Feng Su， Jiaxue Wang，Qian Wang，Suping Niu，Yi Fang*. Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2
diabetes: a network meta-analysis. Diabetes Research and Clinical Practice. 2021；177：108904(1-12) (IF =5.602)
26. Suping Niu, Yan Li, Wenliang Dong, Lin Xia, Tiantian Shen, Jiaxue Wang, Qian Wang, Tan Zhang, Minjie Zhang, Gang Liu, Danjie Guo, Yi Fang*. A randomized study on the
bioequivalence of desloratadine in Chinese healthy subjects and the association of different metabolic phenotypes with UGT2B10 and CYP2C8 genotypes. Current Drug Metabolism.
2020,21:1031-1039. (IF=2.960)
27. Wenliang Dong, Xiaoyan Nie, Jiaxue Wang, Lin Xia, Lin Cai, Qian Wang, Wei Wang, Weixing Fu, Qi Wang, Tiantian Shen, Huaying Fan, Suping Niu, Yimin Cui, Qingshan Zheng,
Jianzhong Zhang, Yi Fang*. Study protocol for a randomized, double-blind, multicenter, phaseI/II dose escalation and expansion trial of GR1501 in patients with plaque psoriasis.
BMJ OPEN. 2020;10:e039067. (IF=2.692)
28. Wenliang Dong, Min Chen, Jiaxue Wang, Lin Xia, Qian Wang, Xiaoyan Nie, Yufei Feng, Yi Fang*. rHuPH20-facilitated subcutaneous administration of monoclonal antibodies in
cancer therapy. Immunotherapy. 2021 Jan;13(1):79-88. (IF=4.196)
29. Tiantian Shen, lin Xia, Wenliang Dong, Jiaxue Wang, Feng Su, Suping Niu, Qian Wang, Yi Fang*. A Systematic Review and Meta-analysis: Safety and Efficacy of Mesenchymal
stem Cells Therapy for Heart Failure. Current Stem Cell Research &Therapy. 2021;16:354-365. (IF=3.828)
30. Chang Liu , Wenliang Dong , Lin Xia , Jie Lv , Daoli Jiang , Qian Wang , Mei Wang , Maofeng Wu , Jingwei Miao , Tao Tao , Dong Wang , Lili Zheng , Shiguang Su , Lizhong Liu ,
Yi Fang*. The Safety and Tolerability of a Humanized Rabbit Monoclonal Antibody (SSS07) in Healthy Adults: Randomized Double-Blind Placebo-controlled Single Ascending
Dose Trial. International Immunopharmacology. 2021; 91:107263(1-9). (IF =4.939)
31. Huaning Kang, Jinhua Zhang, Xiaoting Zhang, Guicheng Qin, Ke Wang, Zhenyu Deng, Yi Fang*, Guihong Chen. Effects of sacubitril/valsartan in patients with heart failure and
chronic kidney disease: A meta-analysis. European Journal of Pharmacology. 884（2020）173444:1-7. (IF=3.263)
32. Jiaxue Wang, Suping Niu, Wenliang Dong, Li Wei, Lun Ou, Tan Zhang, Liangbi Zhang, Xiaoyan Nie, Qian Wang, Tiantian Shen, Qi Wang, Lin Xia, Gang Liu, Jiting Jing,
Qing shan Zheng, Haifeng Song & Yi Fang*. A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human
HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults. Expert Opinion On Investigational Drugs. 2020,29(7):755-762. (IF=5.081)
33. Huihui Dai, Chang Liu, Peijuan Li, Zhangfeng Mai, Xiaoming Tan, Sijing Chen, Ziling Zhou, Zhiben Tang, Jingwei Miao, Lizhong Liu, Yi Fang*. Risk of Dyslipidaemia Associated
with VEGF/VEGFR Inhibitors A Meta-analysis. Translational Oncology. 2020; 13:100779(1-8). (IF=3.558)